Ulm University Hospital
Centre for Personalised Medicine - Oncological Diseases (ZPM)
Patients with advanced or rare tumours for whom no more guideline-based
therapies are available and for whom molecular genetic testing
is therefore being considered or has been carried out are discussed in the Molecular and Familial Tumour Board (MoFa) at
CCCU at Ulm University Hospital. There, innovative treatment options
are developed jointly by clinicians and
scientists on the basis of molecular diagnostics and an evidence-based treatment or screening
recommendation is made.
In addition, patients with known hereditary tumour diseases (tumour disposition syndromes/TDS) can be presented. Patients suspected of having a hereditary tumour disease can also be identified as part of the diagnostic process. These people are then offered human genetic counselling.
